1. MARKETS
  2. SECTOR : PHARMA & BIOTECH
  3. INDUSTRY : MAJOR PHARMACEUTICALS
  4. TAKEDA PHARMACEUTICAL CO - ADR
Takeda Pharmaceutical Co - ADR
XNYS: TAK
Momentum Trap
Download real time
19.840.83(4.37%)
New 52W High today
1.1M
XNYS Volume

XNYS 15 Oct, 2026 10:38 AM (EDT)

Portfolio

Alert

My Notes

Takeda pharma Co (ADR) quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

View Charts

Forecaster Analyst Estimates for Takeda pharma Co (ADR) share price target, revenues, EPS, net income and more

Takeda pharma Co (ADR) quarterly results: revenue, profit, and P&L – 13 quarter history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
Nested row level
Base Level
Export
  • POSITIVE

    Quarterly Revenue Takeda pharma Co (ADR) Jun-2026 Quarterly Revenue is $1,219,900 Million which is growth of 10.2% YoY.

  • NEGATIVE

    Quarterly Net Profit Takeda pharma Co (ADR) Jun-2026 Quarterly Net Profit is $113,197 Million which is growth of -8.9% YoY.

Takeda Pharmaceutical Co - ADR, Earnings Report - Quarterly Results, standalone, All financials are in JPY Million and price data in USD
IndicatorGraphJun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24Sep '24Jun '24Mar '24Dec '23Sep '23Jun '23
Operating Rev.
1,219,9001,094,5411,191,6981,112,7961,106,6851,053,3991,144,1241,176,0381,207,9901,050,8691,111,1861,043,0891,058,618
Cost Of Rev.
406,676405,704401,148380,061384,675382,078416,874394,311386,954382,501379,481343,582321,114
Gross Profit
813,224688,837790,550732,735722,010671,321727,250781,727821,036668,368731,705699,507737,504
⌄
611,807646,769621,728663,739537,445602,778749,698508,089654,708571,558677,037748,849568,933
Operating Profit
201,41742,068168,82268,996184,56568,543-22,448273,638166,32896,81054,668-49,342168,571
⌄
-39,237-35,876-35,756-38,742-33,400-9,733-38,584-64,338-29,014-13,901-44,779-48,663-33,120
Profit Before Tax
162,718-455,023133,86428,174150,630-107,29926,407119,372136,604-47,52261,260-95,980135,033
Tax
49,462-86,61530,13139,90326,351-4,2012,57227,26641,304-44,528-44,496-48,00945,627
⌄
113,197-368,471103,640-11,802124,243-103,15523,78992,04695,248-3,018105,720-48,03089,395
Diluted NI Avail to Com Stockholders Ann.
113,197-368,471103,640-11,802124,243-103,15523,78992,04695,248-3,018105,720-48,03089,395
Basic EPS
35.8-11732.9-3.939.7-32.77.429.130.4-133.8-15.328.8
Diluted EPS After ExtraOrdinary
35.3-11732.3-3.939.1-32.77.328.630-133.4-15.328.6
Number Of Shares End
3,159.83,158.63,157.53,154.93,129.53,252.43,075.13,165.73,137.83,209.73,063.53,130.63,108.8
Net Income Continuing Discontinued Operations
113,197-368,471103,640-11,802124,243-103,15523,78992,04695,248-3,018105,720-48,03089,395
Normalized Income
242,900140,500235,000212,300237,000126,940.5209,800201,600276,800118,669.5235,90057,280.3104,961.5
Interest Income
24,608-189,14787,87144,39673,758-8,167-6,9884,11630,677-34,80821,7899,35926,455
Interest
63,845-165,800123,62783,138107,158-22,43031,59668,45459,691-53,12866,56858,02259,575
Net Interest Income
-39,237-35,876-35,756-38,742-33,400-9,733-38,584-64,338-29,014-13,901-44,779-48,663-33,120
EBIT
201,955-431,676169,62066,916184,030-121,56264,991183,710165,618-65,842106,039-47,317168,153
EBITDA
312,883-267,806360,259251,898365,66668,207251,946376,162357,838120,902293,100135,379339,654
Reconciled Cost Of Rev.
406,676396,671352,423400,234334,677395,384392,594316,511357,565340,871329,758401,128279,036
Reconciled Depr.
110,928163,870190,639184,982181,636189,769186,955192,452192,220186,744187,061182,696171,501
Profit From Continuing Operations
--368,408103,733-11,729124,279-103,09823,83592,10795,299-2,994105,755-47,97089,406
Normalized EBITDA
337,491-456,953448,130316,467439,42473,346244,958380,278388,51586,094314,889202,284366,109
*All financials are in JPY Million and price data in USD
Add metric to table
Search...

Takeda pharma Co (ADR) competitor comparison and performance snapshot within industry

Takeda pharma Co (ADR) annual results: revenue, profit, P&L, and margins as of Mar 2026 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • NEGATIVE

    Annual Revenue Takeda pharma Co (ADR) Mar-2026 Annual Revenue is $4,505,720 Million which is growth of -1.7% YoY.

  • NEGATIVE

    Annual Net Profit Takeda pharma Co (ADR) Mar-2026 Annual Net Profit is $-152,390 Million which is growth of -241.2% YoY.

Takeda Pharmaceutical Co - ADR, Earnings Report - Annual Results, standalone, All financials are in JPY Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsTTMMar '26Mar '25Mar '24Mar '23Mar '22Mar '21Mar '20Mar '19Mar '18Mar '17Mar '16
⌄
3.8%
7.1%
 4,505,7204,581,5514,263,7624,027,4783,569,0063,197,8123,291,1882,097,2241,770,5311,732,0511,807,378
Cost Of Rev. Ann.
8.1%
9.6%
1,593,5891,571,5881,580,2171,426,6781,244,0721,106,846994,3081,089,764659,690495,921558,755535,405
Gross Profit Ann.
1.8%
5.9%
3,025,3462,934,1323,001,3342,837,0842,783,4062,462,1602,203,5042,201,4241,437,5341,274,6101,173,2961,271,973
Operating Exp. Ann.
3.6%
6.6%
2,544,0432,469,6812,515,2732,516,1312,220,8341,929,1411,792,2531,926,7161,277,1691,032,8211,017,4291,141,145
Operating Profit Ann.
-6.2%
2.5%
481,303464,451486,061320,953562,572533,019411,251274,708160,365241,789155,867130,828
⌄
-
-
-149,611-143,774-141,669-140,463-135,641-125,642-137,846-146,649-60,9597,615-10,976-10,286
Other Exp. Ann.
-
-
 -463,032-169,306-127,697-51,840-104,80892,830-188,813-4,510-32,199-1,546-3
PBT Ann.
-
-
-130,267-142,355175,08452,791375,090302,571366,235-60,75494,896217,205143,346120,539
Tax Ann.
-44.8%
-
32,8819,77066,941-91,40658,05272,405-9,936-105,044-14,11830,49727,83337,059
⌄
-
-
-163,436-152,390107,928144,067317,017230,059376,00544,241109,126186,886114,94080,166
Diluted NI Avail to Com Stockholders Ann.
-
-
-163,436-152,390107,928144,067317,017230,059376,00544,241109,126186,886114,94080,166
EPS Ann.
-
-
 -48.434.246102.173.6120.414.256.8119.773.651.1
Diluted EPS Ann.
-
-
 -48.433.645.610172.9119.514.156.4118.873.150.9
Number Of Shares End
0.5%
0.2%
 3,158.63,252.43,209.73,108.53,107.63,126.53,187.43,109.61,562.51,561.71,567
Total Exp. Ann.
5.3%
7.7%
 4,041,2694,095,4903,942,8093,464,9063,035,9872,786,5613,016,4801,936,8591,528,7421,576,1841,676,550
Net Income Continuing Discontinued Operations Ann.
-
-
-163,436-152,390107,928144,067317,017230,059376,00544,241109,126186,886114,94080,166
Normalized Income Ann.
19.7%
4.4%
830,700814,100317,031.4756,900475,066351,566.3655,500247,966.198,303.1134,321.122,383.784,353.9
Interest Income Ann.
45.2%
56.8%
-32,27216,87819,63811,2935,5084,5911,78111,2026,61939,54312,27421,645
Interest Ann.
8.2%
2.5%
104,810148,123137,311119,535116,973122,432130,806149,01048,15831,92823,25031,931
EBITDA Ann.
-12.9%
-6.4%
657,234759,3571,105,992889,0351,150,9551,003,5631,054,931660,703408,881391,717377,109328,206
Reconciled Cost Of Rev. Ann.
9.8%
11.6%
1,556,0041,484,0051,462,0541,350,7931,122,115996,610856,501961,535590,616435,925492,685463,164
Reconciled Depr. Ann.
2.8%
5.2%
650,419721,127761,396728,002664,400583,151559,671583,649272,446182,127222,787197,381
Profit From Continuing Operations Ann.
-
-
 -152,125108,143144,197317,038230,166376,17144,290109,014186,708115,51383,480
Normalized EBITDA Ann.
-0.9%
4.3%
645,1351,187,7501,239,1111,034,4981,222,0891,106,077963,958836,731376,383431,260389,383349,851
*All financials are in JPY Million and price data in USD
Add metric to table
Search...
Total Rev. Ann.
1Y CHG
-1.7%
2Y CAGR
2.8%
3Y CAGR
3.8%
5Y CAGR
7.1%
7Y CAGR
11.5%
10Y CAGR
9.6%
Total Revenue Annual is falling faster than historical averages.
Operating Exp. Ann.
1Y CHG
-1.8%
2Y CAGR
-0.9%
3Y CAGR
3.6%
5Y CAGR
6.6%
7Y CAGR
9.9%
10Y CAGR
8%
Operating Expenses Annual Cr is falling faster than historical averages.

Takeda pharma Co (ADR) balance sheet as of Mar 2026: assets, liabilities, reserves, and borrowings – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • POSITIVE

    Total Shareholders Fund Takeda pharma Co (ADR) Mar-2026 Total Shareholders Fund is $7,429,441 Million which is growth of 7.1% YoY.

  • POSITIVE

    Total Assets Takeda pharma Co (ADR) Mar-2026 Total Assets is $15,511,506 Million which is growth of 8.9% YoY.

Takeda Pharmaceutical Co - ADR, Balance Sheet, standalone, All financials are in JPY Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsMar '26Mar '25Mar '24Mar '23Mar '22Mar '21Mar '20Mar '19Mar '18Mar '17Mar '16
⌄
3.6%
3.7%
15,511,50614,248,34415,108,79213,957,75013,178,01812,912,29312,821,09413,872,3224,106,4634,355,7823,824,085
⌄
2.1%
0.9%
8,080,8577,312,3657,834,7877,603,0797,494,4957,735,1168,093,6088,708,7342,089,0542,406,8171,812,882
⌄
5.3%
7.5%
7,429,4416,935,0847,273,2646,354,1225,683,0195,173,0374,723,4835,159,5821,997,4241,894,2611,948,692
Total Capitalization Ann.
4.3%
3.8%
11,799,12210,901,41011,749,76510,396,8639,824,4379,786,2559,229,9709,925,5872,983,0682,494,1232,488,452
Tangible Assets Ann.
-
-
-1,798,917-2,020,906-2,411,486-2,706,258-2,543,275-2,769,986-3,460,406-3,862,189-46,088-194,285426,248
Working Capital Ann.
-
-22.8%
258,42914,671245,477-83,984447,912939,717293,534539,727341,299-105,429516,574
Invested Capital Ann.
4.7%
4.7%
12,311,27911,450,34912,117,01610,736,46310,028,4309,808,4089,816,78710,910,5332,983,0863,039,1512,716,916
Tangible Book Value Ann.
-
-
-1,798,917-2,020,906-2,411,486-2,706,258-2,543,275-2,769,986-3,460,406-3,862,189-46,088-194,285426,248
Borrowings Ann.
3.7%
1%
4,881,8384,515,2654,843,7524,382,3414,345,4114,635,3715,093,3045,750,951985,6621,144,890768,224
Net Debt Ann.
3.7%
3.2%
4,286,7844,130,1524,385,9523,848,8113,495,7163,669,1494,455,6905,048,858691,140825,435316,798
Share Issued Ann.
0.2%
0.2%
1,591.21,5911,582.41,582.31,582.31,576.41,576.41,565781.3780.8783.5
Number Of Shares End
0.5%
0.2%
3,158.63,252.43,209.73,108.53,107.63,126.53,187.43,109.61,562.51,561.71,567
*All financials are in JPY Million and price data in USD
Add metric to table
Search...
Total Assets Ann.
1Y CHG
8.9%
2Y CAGR
1.3%
3Y CAGR
3.6%
5Y CAGR
3.7%
7Y CAGR
1.6%
10Y CAGR
15%
Total Assets Annual growth is higher than historical averages.
Total Current Liabilities Ann.
1Y CHG
13%
2Y CAGR
10.7%
3Y CAGR
4.5%
5Y CAGR
9.8%
7Y CAGR
1.7%
10Y CAGR
12.7%
Total Current Liabilities Annual Cr growth is higher than historical averages.
Total ShareHolders Funds Ann.
1Y CHG
7.1%
2Y CAGR
1.1%
3Y CAGR
5.3%
5Y CAGR
7.5%
7Y CAGR
5.3%
10Y CAGR
14.3%
Total ShareHolders Funds Annual growth is stable compared to historical averages.

Takeda pharma Co (ADR) ROE, ROCE, book value, and debt-to-equity ratio as of Mar 2026 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • POSITIVE

    Book Value Per Share Takeda pharma Co (ADR) Book Value Per Share is $15 which is growth of 0.1% YoY.

  • POSITIVE

    ROE Takeda pharma Co (ADR) ROE is -2% which is growth of 3.6% YoY.

Takeda Pharmaceutical Co - ADR, Ratios, standalone, All financials are in JPY Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsMar '26Mar '25Mar '24Mar '23Mar '22Mar '21Mar '20Mar '19Mar '18Mar '17Mar '16
RoA Ann. %
-
-
-1.02%0.74%0.99%2.34%1.76%2.92%0.33%1.21%4.42%2.81%1.97%
ROE Ann. %
-
-
-2.12%1.52%2.11%5.27%4.24%7.60%0.90%3.05%9.60%5.98%3.92%
ROIC %
-
-
-2.8-1-0.20.502.20.3-0.6-2-1.6-1.3
OPM Ann. %
-9.6%
-4.3%
10.31%10.61%7.53%13.97%14.93%12.86%8.35%7.65%13.66%9.00%7.24%
Inventory Turnover Ratio Ann.
-5%
-1.6%
1.21.31.31.41.41.31.31.12.32.32.1
Asset Turnover Ann. %
0%
0%
0.30.30.30.30.30.30.30.20.40.40.5
Working Capital Turnover Ann.
-
38.6%
17.4312.317.4-4883.411.23.95.2-16.43.5
Quick Ratio Ann.
0%
-12.9%
0.50.50.50.50.810.70.61.10.61.2
Current Ratio Ann.
3.2%
-6%
1.111.111.21.51.11.21.50.91.6
Interest Coverage Ratio Ann.
-
-
02.31.44.23.53.80.637.87.24.8
LT Debt To Equity Ann.
0%
-7.8%
0.60.60.60.60.70.910.90.50.30.3
*All financials are in JPY Million and price data in USD
Add metric to table
Search...
Current Ratio Ann.
1Y CHG
10%
3Y CAGR
3.2%
5Y CAGR
-6%
7Y CAGR
-1.2%
10Y CAGR
-3.7%
Current Ratio Annual growth is higher than historical averages.

Takeda pharma Co (ADR) cash flow: net, operating, investing, and financing flows as of Mar 2026 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • NEGATIVE

    Cash From Operating Activity Takeda pharma Co (ADR) Mar-2026 Cash From Operating Activity is $1,041,432 Million which is growth of -1.5% YoY.

  • POSITIVE

    Net Cash Flow Takeda pharma Co (ADR) Mar-2026 Net Cash Flow is $175,472 Million which is growth of 386.2% YoY.

Takeda Pharmaceutical Co - ADR, Cash Flow, standalone, All financials are in JPY Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsMar '26Mar '25Mar '24Mar '23Mar '22Mar '21Mar '20Mar '19Mar '18Mar '17Mar '16
⌄
2.1%
0.6%
1,041,4321,057,181716,344977,1571,123,1071,010,931669,752328,479377,854261,36525,491
⌄
-
-
-369,141-367,061-463,861-607,102-198,126393,530292,119-2,835,698-93,342-655,689-71,210
⌄
-
-
-496,819-751,423-354,415-709,149-1,070,265-1,088,354-1,005,2132,946,237-326,226289,896-124,838
Cash Plus Cash Eqv. End Of Year Ann.
3.7%
-9.2%
595,054385,113457,800533,530849,695966,222637,614702,093294,522319,455451,426
Net Increase In Cash Plus Cash Eqv.s Ann.
-
-11.1%
175,469-61,302-101,934-339,094-145,285316,107-43,342439,018-41,714-104,431-170,557
Cash Plus Cash Eqv. Begin Of Year Ann.
-23.2%
-9.6%
385,113457,800533,530849,695966,222637,614702,722294,973341,252451,426655,243
Income Tax Paid Supplemental Data Ann.
-
-
-----------
Interest Paid Supplemental Data Ann.
-
-
-----------
Capex Ann.
-
-
-414,659-379,625-480,730-633,689-186,037-236,468-217,710-134,114-128,262-112,027-84,857
Issuance Of Capital Stock Ann.
-
-
-----------
Issuance Of Debt Ann.
98.4%
-13.1%
586,0601,051,950100,00075,000249,3341,179,515496,1902,795,926393,453260,226150,000
Repayment Of Debt Ann.
-
-
-584,984-1,366,264-375,487-400,071-849,811-1,690,976-731,057-1,741-142,658-191,763-100,012
Repurchase Of Capital Stock Ann.
-
-
-51,603-51,860-2,326-26,929-77,531-2,141-3,737-1,172-18,756-23,117-22,346
Free Cash Flow Ann.
29.1%
-5.4%
505,393564,572135,239234,913828,863667,113324,831159,451241,227142,367-64,255
*All financials are in JPY Million and price data in USD
Add metric to table
Search...
Cash from Operating Act. Ann.
1Y CHG
-1.5%
2Y CAGR
20.6%
3Y CAGR
2.1%
5Y CAGR
0.6%
7Y CAGR
17.9%
10Y CAGR
44.9%
Cash from Operating Activity Annual is falling faster than historical averages.
×